<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973423</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC IR 2020 BUISSON</org_study_id>
    <nct_id>NCT04973423</nct_id>
  </id_info>
  <brief_title>STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP</brief_title>
  <acronym>Deeper</acronym>
  <official_title>STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can dramatically&#xD;
      affect the quality of life of patients. Due to its transmural nature (involvement of the&#xD;
      entire thickness of the intestinal wall), it naturally progresses to intestinal destruction&#xD;
      (stenosis, fistula) which requires intestinal resection in approximately half of patients&#xD;
      during their follow-up. The long-term goal for patients is to maintain a normal life, that&#xD;
      is, without symptoms and without intestinal destruction. For this, the short and medium term&#xD;
      therapeutic objectives have evolved in recent years. Clinical remission is not a sufficient&#xD;
      goal since it has failed to alter the natural history of the disease. The current objective&#xD;
      to be achieved is the combination of clinical remission and endoscopic mucosal healing since&#xD;
      it is associated with a reduced risk of progression (reappearance of symptoms,&#xD;
      hospitalization, intestinal resection). Fecal calprotectin, better accepted than colonoscopy,&#xD;
      is a non-invasive biomarker of endoscopic inflammatory activity in CD. The CALM study&#xD;
      recently showed that close follow-up with clinical and biological evaluation (assays of CRP&#xD;
      and fecal calprotectin), called &quot;tight control&quot;, associated with therapeutic intensification&#xD;
      in the absence of clinical or biological remission, was associated with a better rate of&#xD;
      endoscopic mucosal healing at 1 year than follow-up based solely on symptoms. Thus, the&#xD;
      &quot;CALM&quot; strategy is considered to be the current benchmark.&#xD;
&#xD;
      Transmural healing evaluated by MRI is also a promising objective associated with a reduced&#xD;
      risk of progression (reappearance of symptoms, hospitalization, bowel resection). In&#xD;
      addition, it could prevent intestinal destruction. A recent study by our team suggested that&#xD;
      calprotectin (mucosal assessment) and MRI (transmural assessment) may be complementary and be&#xD;
      a better therapeutic goal. We hypothesize that a &quot;CALM + MRI&quot; strategy concomitantly&#xD;
      targeting transmural healing would be superior to the &quot;CALM&quot; strategy alone in maintaining&#xD;
      clinical remission without corticosteroids in patients with CD treated with biotherapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label controlled study comparing two therapeutic strategies in&#xD;
      patients with CD (see inclusion criteria) starting biotherapy. Randomization, by minimization&#xD;
      (Stata version 15), will be stratified by center, by biotherapy line and on the location of&#xD;
      the disease: MC colic isolated (L2 according to the Montreal classification) vs. Ileal or&#xD;
      ileocolic MC (L1 + L3), for a maximum of L1 + L3 patients of 70%.&#xD;
&#xD;
      The reference arm will be based on that of the CALM study, i.e. regular follow-up (S0, S12,&#xD;
      S24, S52, S76, S100, S124 and S152) with therapeutic intensification in the absence of at&#xD;
      least one criterion among CDAI &lt;150, CRP &lt;5 or fecal calprotectin &lt;250. After checking the&#xD;
      inclusion criteria, the patients will be included and randomized. The initial choice of&#xD;
      biotherapy, therapeutic intensifications (dose increase, interval reduction, treatment&#xD;
      change) and treatment sequences will be based on the French consensus of 2020. MRI will be&#xD;
      performed in all patients at weeks 0, 76 and 152. In the MRI arm, an additional MRI will be&#xD;
      performed at W24 and W52 with therapeutic intensification at W24, W52 and W76 in the presence&#xD;
      of residual MRI activity. Patients will be followed for 152 weeks (≈ 3 years). In the event&#xD;
      of a missing examination (calprotectin or MRI), the intensification will be carried out or&#xD;
      not with the available data. Therefore, the analysis will be performed by intention to treat&#xD;
      (ITT). Patients will be given a symptom calendar (abdominal pain score (between 0 = no pain&#xD;
      and 3 = severe pain) and number of stools). Each month without data (lost to follow-up) will&#xD;
      be considered as in the absence of clinical remission without corticosteroids (ITT). The&#xD;
      fecal calprotectin dosage will be standardized and performed with the same test in all&#xD;
      patients. Therapeutic intensification based on MRI will be carried out after a centralized&#xD;
      review. The secondary endpoints (response and transmural healing, Lémann index) will be&#xD;
      centrally blinded in the study arm to avoid any evaluation bias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of months spent in clinical remission</measure>
    <time_frame>Between week 24 and week 76.</time_frame>
    <description>Proportion of months (4 week period) spent in clinical remission without corticosteroids according to PRO-2 (&lt;3 very soft or watery stools per day and no moderate to severe abdominal pain).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Calprotectin</condition>
  <condition>MRI</condition>
  <arm_group>
    <arm_group_label>CALM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Tight control of inflammatory activity by calprotectin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CALM + IRM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tight control of inflammatory activity by calprotectin associated with transmural evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>2 additional MRI will be done for the CALM + MRI group</description>
    <arm_group_label>CALM + IRM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Crohn's disease (age ≥ 18 years)&#xD;
&#xD;
          -  Symptomatic with Crohn's disease activity index (CDAI)&gt; 150&#xD;
&#xD;
          -  Presence of objective signs of inflammatory activity (fecal calprotectin&gt; 250 AND sign&#xD;
             of MRI activity)&#xD;
&#xD;
          -  Requiring treatment with biotherapy according to the investigator&#xD;
&#xD;
          -  Able to give informed consent to participate in research&#xD;
&#xD;
          -  Affiliation to a Social Security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe obstructive symptoms&#xD;
&#xD;
          -  Uncontrolled intra-abdominal abscess&#xD;
&#xD;
          -  Isolated anoperineal lesions&#xD;
&#xD;
          -  Prevention of postoperative endoscopic recurrence&#xD;
&#xD;
          -  Temporary or definitive ostomy&#xD;
&#xD;
          -  Total colectomy&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Protected adults (curatorship, guardianship, saving justice)&#xD;
&#xD;
          -  Refusal of participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>04 73 75 11 95</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens university hospital</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>MAthurin FUMERY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurillac Hospital</name>
      <address>
        <city>Aurillac</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Clément PASTAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bayonne hospital</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Félix GOUTORBE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux university hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>David LAHARIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chambery Hospital</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christophe Allimant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anthony BUISSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nicolas MATHIEU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Issoire Hospital</name>
      <address>
        <city>Issoire</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Camille Sautel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LILLE university hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Maria NACHURY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon Hospital, Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stéphane NANCEY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montluçon Hospital</name>
      <address>
        <city>Montluçon</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Cédric DURON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montpellier University hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Romain ALTWEGG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy University hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Laurent PEYRIN-BIROULET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nice University hospital</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xavier HEBUTERNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Guillaume BOUGUEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Etienne University Hospital</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xavier ROBLIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thiers Hospital</name>
      <address>
        <city>Thiers</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Julien SCANZI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

